Sandbox:landing lung: Difference between revisions
No edit summary |
|||
Line 31: | Line 31: | ||
{{Familytree/start}} | {{Familytree/start}} | ||
{{Familytree | | | | | | | A01 | | | | | | A01= <div style="float: left; text-align:center; width: 15em; padding:1em;">'''Liver mass detected'''</div>}} | {{Familytree | | | | | | | A01 | | | | | | A01= <div style="float: left; text-align:center; width: 15em; padding:1em;">'''Liver mass detected'''<br><SMALL> Adapted from Bonder et al.</SMALL></div>}} | ||
{{Familytree | | | | | | | |!| | | | | | | }} | {{Familytree | | | | | | | |!| | | | | | | }} | ||
{{Familytree | | | | | | | A02 | | | | | | A02= <div style="float: left; text-align:center; width: 15em; padding:1em;">'''Relevant medical history to obtain:'''</div>}} | {{Familytree | | | | | | | A02 | | | | | | A02= <div style="float: left; text-align:center; width: 15em; padding:1em;">'''Relevant medical history to obtain:'''</div>}} |
Revision as of 18:37, 25 March 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Pulmonary mass is generally defined as any area of pulmonary opacification that measures more than 30 mm in the lung. Pulmonary mass can be benign or malignant. On the other hand, pulmonary nodule is defined as a relatively well defined round or oval pulmonary parenchymal lesion equal or smaller than 30 mm in diameter. Pulmonary nodule can be classified into 2 categories: solitary or multiple.
Classification
For more details about each specific type of condition, click on the links in blue in the algorithm below.
In order to distinguish pulmonary mass from solitary pulmonary nodule, click here [Insert link to big table of differentials]
Pulmonary nodule/mass | |||||||||||||||||||||||||||||||||
More than > 30 mm | Less than <30 mm | ||||||||||||||||||||||||||||||||
Multiple | Single | ||||||||||||||||||||||||||||||||
Liver
}}Liver mass detected Adapted from Bonder et al. | |||||||||||||||||||||||||||||||||
Relevant medical history to obtain: | |||||||||||||||||||||||||||||||||
❑ Age and gender ❑ Symptoms: jaundice, pain, nausea ❑ Recent travel ❑ Hepatitis serology ❑ Iron studies ❑ Use of oral contraceptives ❑ AFP levels ❑ From endemic area of hepatitis ❑ History of chronic liver disease ❑ Physical findings | |||||||||||||||||||||||||||||||||
Chronic liver disease Hepatitis B or C | No history of chronic liver disease | ||||||||||||||||||||||||||||||||
Check AFP, triphasic CT or MRI Follow-up screening guidelines as cirrhotic patient | Benign characteristics of a liver mass Follow-up accordingly | ||||||||||||||||||||||||||||||||